A biotech client engaged Piramal Pharma Solutions'; Riverview, Michigan drug substance facility to develop and manufacture a complex payload-linker intended to feed multiple antibody-drug conjugate (ADC) programs.
-1.png)
Early-stage development needs to be fast-paced and is inherently unpredictable. Evidence emerges, priorities evolve, and both sponsors and partners need to adapt quickly to keep advancing therapeutic compounds swiftly toward the patients who need them, with a consistent quality profile.
Piramal has developed a novel process to prepare gliflozins. The new platform technology, which can be applied to any of the gliflozins, involves in-situ reactions with high yields and purity and brings down the cost of manufacturing substantially as compared to prior processes.
The Piramal Pharma Solutions (PPS) site located at Morpeth, England, is a significant manufacturer of various active pharmaceutical ingredients (APIs) needed for the synthesis of important drugs. Due to escalating energy costs and increasing environmental concerns, employees at the Morpeth site worked together to analyze current processes and develop new ways to move forward that are considerate of energy consumption and potential impacts on global health. To focus these efforts, this massive project was further divided into 4 phases: reduction, replacement, generation, and procurement of energy.
The Solvent Efficiency Improvement Initiative at the Piramal Pharma Solutions (PPS) Digwal, India site was part of a larger program called ‘Project Phoenix';, a site-wide initiative aimed at transforming the use and handling of solvents. The active pharmaceutical ingredients (API) manufacturing plant uses a significant quantity of solvents and plays a critical role in the production of pharmaceutical products, but excessive consumption and low recoveries can pose multiple challenges, including the generation of waste and impacts on the environment.
